Secukinumab for treating non-radiographic axial spondyloarthritis - Final Appraisal Document

In DRAFT guidance, NICE recommends secukinumab for active nonradiographic axial spondyloarthritis inadequately controlled with NSAIDs, only if TNF-alpha inhibitors unsuitable or do not control the condition well enough and it is provided according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence